{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Transforming Bladder Cancer Care: A Conversation with Dr. Mark Schoenberg","description":"In this episode of Bladder Cancer Matters, host and survivor Rick Bangs sits down with Dr. Mark Schoenberg\u2014renowned urologist and Chief Medical Officer at UroGen\u00ae Pharma\u2014for a wide-ranging conversation about the evolution of bladder cancer research, treatment, and patient advocacy. Dr. Schoenberg shares the story behind BCAN\u2019s founding, the early challenges of raising awareness, and the innovations that are reshaping care today, including the development of non-surgical therapies like ZUSDURI\u2122 (mitomycin) for intravesical solution, a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after you have previously received bladder surgery to remove the tumor and it did not work or is no longer working. From his decades of patient-centered work to his role in pioneering new approaches with UroGen, Dr. Schoenberg offers insights into where the field has been and the promising future ahead. Tune in to hear a fascinating mix of history, science, and hope for patients and families impacted by bladder cancer. Please see the link to the full Prescribing Information on the podcast web page or available at www.zusduri.com.  ZUSDURI Prescribing Information ZUSDURI Patient Information Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment. J Urol. 2024;10.1097\/JU.0000000000003846. ZUSDURI (mitomycin) for intravesical solution is a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after you have previously received bladder surgery to remove tumor and it did not work or is no longer working. ZUSDURI\u2122 Important Safety Information You should not receive ZUSDURI\u2122 if you have a hole or tear (perforation) of your bladder or if you have had an allergic reaction to mitomycin or to any of the ingredients in ZUSDURI\u2122. Before receiving ZUSDURI\u2122, tell your healthcare provider about all of your medical conditions, including if you: have kidney problems are pregnant or plan to become pregnant. ZUSDURI\u2122 can harm your unborn baby. You should not become pregnant during treatment with ZUSDURI\u2122. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ZUSDURI\u2122. Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with ZUSDURI\u2122 and for 6 months after the last dose. Males being treated with ZUSDURI\u2122: You should use effective birth control (contraception) during treatment with ZUSDURI\u2122 and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if ZUSDURI\u2122 passes into your breast milk. Do not breastfeed during treatment with ZUSDURI\u2122 and for 1 week after the last dose. How will I receive ZUSDURI\u2122? You will receive your ZUSDURI\u2122 dose from your healthcare provider 1 time a week for 6 weeks into your bladder through a tube called a urinary catheter. It is important that you receive all 6 doses of ZUSDURI\u2122 according to your healthcare provider's instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. During treatment with ZUSDURI\u2122, your healthcare provider may tell you to take additional medicines or change how you take your current medicines. After receiving ZUSDURI\u2122: ZUSDURI\u2122 may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 24 hours. To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water. Clothing that comes in contact with urine should be washed right away and washed separately from other clothing. The most common side effects of ZUSDURI\u2122 include: increased blood creatinine levels, increased blood potassium levels, trouble with urination, decreased red blood cell counts, increase in certain blood liver tests, increased or decreased white blood cell counts, urinary tract infection, blood in your urine. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov\/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436. Please see ZUSDURI Full Prescribing Information, including the Patient Information, for additional information.  JELMYTO\u00ae Important Safety Information You should not receive JELMYTO\u00ae if you have a hole or tear (perforation) of your bladder or upper urinary tract. Before receiving JELMYTO\u00ae, tell your healthcare provider about all your medical conditions, including if you are pregnant or plan to become pregnant. JELMYTO\u00ae can harm your unborn baby. You should not become pregnant during treatment with JELMYTO\u00ae. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO\u00ae. Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with JELMYTO\u00ae and for 6 months after the last dose. Males being treated with JELMYTO\u00ae: If you have a female partner who is able to become pregnant, you should use effective birth control (contraception) during treatment with JELMYTO\u00ae and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if JELMYTO\u00ae passes into your breast milk. Do not breastfeed during treatment with JELMYTO\u00ae and for 1 week after the last dose. Tell your healthcare provider if you take water pills (diuretic). How will I receive JELMYTO\u00ae? Your healthcare provider will tell you to take a medicine called sodium bicarbonate before each JELMYTO\u00ae treatment. You will receive your JELMYTO\u00ae dose from your healthcare provider 1 time a week for 6 weeks. It is important that you receive all 6 doses of JELMYTO\u00ae according to your healthcare provider\u2019s instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. Your healthcare provider may recommend up to an additional 11 monthly doses. JELMYTO\u00ae is given to your kidney through a tube called a catheter. During treatment with JELMYTO\u00ae, your healthcare provider may tell you to take additional medicines or change how you take your current medicines. After receiving JELMYTO\u00ae: JELMYTO\u00ae may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 6 hours. To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water. Clothing that comes in contact with urine should be washed right away and washed separately from other clothing. JELMYTO\u00ae may cause serious side effects, including: Swelling and narrowing of the tube that carries urine from the kidney to the bladder (ureteric obstruction). If you develop swelling and narrowing, and to protect your kidney from damage, your healthcare provider may recommend the placement of a small plastic tube (stent) in the ureter to help the kidney drain. Tell your healthcare provider right away if you develop side pain or fever during treatment with JELMYTO\u00ae. Bone marrow problems. JELMYTO\u00ae can affect your bone marrow and can cause a decrease in your white blood cell, red blood cell, and platelet counts. Your healthcare provider will do blood tests prior to each treatment to check your blood cell counts during treatment with JELMYTO\u00ae. Your healthcare provider may need to temporarily or permanently stop JELMYTO\u00ae if you develop bone marrow problems during treatment with JELMYTO\u00ae. The most common side effects of JELMYTO\u00ae include: urinary tract infection, blood in your urine, side pain, nausea, trouble with urination, kidney problems, vomiting, tiredness, stomach (abdomen) pain. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http:\/\/www.fda.gov\/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436. Please click here for JELMYTO\u00ae Full Prescribing Information, including the Patient Information, for additional information.   ","author_name":"Bladder Cancer Matters","author_url":"http:\/\/bladdercancer.libsyn.com\/website","html":"